# Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors

> **NCT03600233** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **TaiRx, Inc.** · enrollment: 34 (actual)

## Conditions studied

- Neuroendocrine Tumors
- Pancreatic Neuroendocrine Tumor
- Gastro-enteropancreatic Neuroendocrine Tumor
- Lung Neuroendocrine Neoplasm
- Neuroendocrine Carcinoma

## Interventions

- **DRUG:** CVM-1118

## Key facts

- **NCT ID:** NCT03600233
- **Lead sponsor:** TaiRx, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-12-15
- **Primary completion:** 2024-09-30
- **Final completion:** 2026-03-31
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2025-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03600233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03600233, "Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03600233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*